176 related articles for article (PubMed ID: 25800646)
21. Hybrids from 4-anilinoquinazoline and hydroxamic acid as dual inhibitors of vascular endothelial growth factor receptor-2 and histone deacetylase.
Peng FW; Wu TT; Ren ZW; Xue JY; Shi L
Bioorg Med Chem Lett; 2015 Nov; 25(22):5137-41. PubMed ID: 26475519
[TBL] [Abstract][Full Text] [Related]
22. SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies.
Hart S; Goh KC; Novotny-Diermayr V; Hu CY; Hentze H; Tan YC; Madan B; Amalini C; Loh YK; Ong LC; William AD; Lee A; Poulsen A; Jayaraman R; Ong KH; Ethirajulu K; Dymock BW; Wood JW
Leukemia; 2011 Nov; 25(11):1751-9. PubMed ID: 21691275
[TBL] [Abstract][Full Text] [Related]
23. Discovery of quinolinone derivatives as potent FLT3 inhibitors.
Chung HJ; Kamli MR; Lee HJ; Ha JD; Cho SY; Lee J; Kong JY; Han SY
Biochem Biophys Res Commun; 2014 Mar; 445(3):561-5. PubMed ID: 24530392
[TBL] [Abstract][Full Text] [Related]
24. Design, synthesis and preliminary bioactivity studies of 1,3,4-thiadiazole hydroxamic acid derivatives as novel histone deacetylase inhibitors.
Guan P; Sun F; Hou X; Wang F; Yi F; Xu W; Fang H
Bioorg Med Chem; 2012 Jun; 20(12):3865-72. PubMed ID: 22579621
[TBL] [Abstract][Full Text] [Related]
25. Design, synthesis, and biological evaluation of 4-((6,7-dimethoxyquinoline-4-yl)oxy)aniline derivatives as FLT3 inhibitors for the treatment of acute myeloid leukemia.
Xu Q; Dai B; Li Z; Xu L; Yang D; Gong P; Hou Y; Liu Y
Bioorg Med Chem Lett; 2019 Oct; 29(19):126630. PubMed ID: 31466809
[TBL] [Abstract][Full Text] [Related]
26. Natural and Synthetic Macrocyclic Inhibitors of the Histone Deacetylase Enzymes.
Maolanon AR; Kristensen HM; Leman LJ; Ghadiri MR; Olsen CA
Chembiochem; 2017 Jan; 18(1):5-49. PubMed ID: 27748555
[TBL] [Abstract][Full Text] [Related]
27. Non-natural macrocyclic inhibitors of histone deacetylases: design, synthesis, and activity.
Auzzas L; Larsson A; Matera R; Baraldi A; Deschênes-Simard B; Giannini G; Cabri W; Battistuzzi G; Gallo G; Ciacci A; Vesci L; Pisano C; Hanessian S
J Med Chem; 2010 Dec; 53(23):8387-99. PubMed ID: 21073160
[TBL] [Abstract][Full Text] [Related]
28. Design, synthesis and biological evaluation of indolin-2-one-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase3 (FLT3).
Ma F; Liu P; Lei M; Liu J; Wang H; Zhao S; Hu L
Eur J Med Chem; 2017 Feb; 127():72-86. PubMed ID: 28038328
[TBL] [Abstract][Full Text] [Related]
29. Design and synthesis of dual-action inhibitors targeting histone deacetylases and 3-hydroxy-3-methylglutaryl coenzyme A reductase for cancer treatment.
Chen JB; Chern TR; Wei TT; Chen CC; Lin JH; Fang JM
J Med Chem; 2013 May; 56(9):3645-55. PubMed ID: 23570542
[TBL] [Abstract][Full Text] [Related]
30. Design, synthesis and biological evaluation of novel indole derivatives as potential HDAC/BRD4 dual inhibitors and anti-leukemia agents.
Cheng G; Wang Z; Yang J; Bao Y; Xu Q; Zhao L; Liu D
Bioorg Chem; 2019 Mar; 84():410-417. PubMed ID: 30554080
[TBL] [Abstract][Full Text] [Related]
31. Structural basis for the design and synthesis of selective HDAC inhibitors.
Di Micco S; Chini MG; Terracciano S; Bruno I; Riccio R; Bifulco G
Bioorg Med Chem; 2013 Jul; 21(13):3795-807. PubMed ID: 23693069
[TBL] [Abstract][Full Text] [Related]
32. Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies.
Liang X; Zang J; Li X; Tang S; Huang M; Geng M; Chou CJ; Li C; Cao Y; Xu W; Liu H; Zhang Y
J Med Chem; 2019 Apr; 62(8):3898-3923. PubMed ID: 30901208
[TBL] [Abstract][Full Text] [Related]
33. Design, synthesis and antiproliferative activities of novel benzamides derivatives as HDAC inhibitors.
Li Y; Wang Y; Xie N; Xu M; Qian P; Zhao Y; Li S
Eur J Med Chem; 2015 Jul; 100():270-6. PubMed ID: 26140961
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and biological evaluation of diaryl urea derivatives as FLT3 inhibitors.
Zhang Q; Zhao K; Zhang L; Jiao X; Zhang Y; Tang C
Bioorg Med Chem Lett; 2020 Dec; 30(23):127525. PubMed ID: 32898697
[TBL] [Abstract][Full Text] [Related]
35. Design and Synthesis of New Sulfonamides-Based Flt3 Inhibitors.
Abutayeh RF; Almaliti J; Taha MO
Med Chem; 2020; 16(3):403-412. PubMed ID: 30931863
[TBL] [Abstract][Full Text] [Related]
36. Discovery of BPR1K871, a quinazoline based, multi-kinase inhibitor for the treatment of AML and solid tumors: Rational design, synthesis, in vitro and in vivo evaluation.
Hsu YC; Coumar MS; Wang WC; Shiao HY; Ke YY; Lin WH; Kuo CC; Chang CW; Kuo FM; Chen PY; Wang SY; Li AS; Chen CH; Kuo PC; Chen CP; Wu MH; Huang CL; Yen KJ; Chang YI; Hsu JT; Chen CT; Yeh TK; Song JS; Shih C; Hsieh HP
Oncotarget; 2016 Dec; 7(52):86239-86256. PubMed ID: 27863392
[TBL] [Abstract][Full Text] [Related]
37. Design, synthesis and biological evaluation of indeno[1,2-d]thiazole derivatives as potent histone deacetylase inhibitors.
Zhou M; Ning C; Liu R; He Y; Yu N
Bioorg Med Chem Lett; 2013 Jun; 23(11):3200-3. PubMed ID: 23639537
[TBL] [Abstract][Full Text] [Related]
38. Novel pyrrole carboxamide inhibitors of JAK2 as potential treatment of myeloproliferative disorders.
Brasca MG; Gnocchi P; Nesi M; Amboldi N; Avanzi N; Bertrand J; Bindi S; Canevari G; Casero D; Ciomei M; Colombo N; Cribioli S; Fachin G; Felder ER; Galvani A; Isacchi A; Motto I; Panzeri A; Donati D
Bioorg Med Chem; 2015 May; 23(10):2387-407. PubMed ID: 25882525
[TBL] [Abstract][Full Text] [Related]
39. Discovery of pyridone-based histone deacetylase inhibitors: approaches for metabolic stability.
Cho M; Choi E; Yang JS; Lee C; Seo JJ; Kim BS; Oh SJ; Kim HM; Lee K; Park SK; Kwon HJ; Han G
ChemMedChem; 2013 Feb; 8(2):272-9. PubMed ID: 23292995
[TBL] [Abstract][Full Text] [Related]
40. Discovery of the first histone deacetylase 6/8 dual inhibitors.
Olson DE; Wagner FF; Kaya T; Gale JP; Aidoud N; Davoine EL; Lazzaro F; Weïwer M; Zhang YL; Holson EB
J Med Chem; 2013 Jun; 56(11):4816-20. PubMed ID: 23672185
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
